Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study.

Acta oncologica (Stockholm, Sweden) - 1 Sept 2021

Alanen Virve, Iivanainen Sanna, Arffman Martti, Koivunen Jussi P

Abstract excerpt

BACKGROUND: With the first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with topical corticosteroids and tetracyclines. This study investigates whether prophylaxis with topical corticosteroids is associated with improved survival among the EGFR TKI-treated non-small cell lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 34137354
DOI: 10.1080/0284186X.2021.1937309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study.PMID 34137354Read ↗

Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study.Semantic proximity Read ↗

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancerSemantic proximity Read ↗

Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity Read ↗

Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.Semantic proximity Read ↗

Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.Semantic proximity Read ↗

Oral Corticosteroid Prescription Trends in South Korea: A 10-Year Nationwide Population-Based Study Using the NHIS-NSCSemantic proximity Read ↗

Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.Semantic proximity Read ↗

Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.Semantic proximity Read ↗

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.